{"url_path":"/sec/mtva/8-k/2026-07-09/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1638287/0001104659-26-082116-index.html","accession_number":"0001104659-26-082116","cik":"0001638287","ticker":"MTVA","issuer_name":"MetaVia Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1638287/0001104659-26-082116-index.html","primary_entity_key":"0001638287","primary_entity_name":"MetaVia Inc."},"word_count":266,"has_tables":true,"body_markdown":"**Item 7.01****Regulation FD Disclosure.**\n\n \n\nOn July 9, 2026, MetaVia Inc. (the **“Company”**)\nissued a press release announcing that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726\nfor the treatment of obesity (the **“Phase 1 Trial”**) have successfully completed dose titration and are now receiving\ntheir highest target doses in both study cohorts, and that topline data from the Phase 1 Trial is on track to be released in the fourth\nquarter of 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this **“Report”**)\nand is incorporated herein by reference.\n\n \n\nInformation contained on or accessible through\nany website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website\naddresses in this Report by incorporation by reference of the press release is as inactive textual references only.\n\n \n\nThe information in Item 7.01 of this Report, including\nExhibit 99.1 attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities\nExchange Act of 1934, as amended (the **“Exchange Act”**), or otherwise subject to the liabilities of that Section,\nnor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange\nAct, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed\nan admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD."}